Evercore ISI Group Maintains Outperform on Avidity Biosciences, Raises Price Target to $54
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group analyst Josh Schimmer maintains an Outperform rating on Avidity Biosciences (NASDAQ:RNA) and raises the price target from $45 to $54.
August 12, 2024 | 2:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evercore ISI Group analyst Josh Schimmer maintains an Outperform rating on Avidity Biosciences and raises the price target from $45 to $54.
The raised price target and maintained Outperform rating by a reputable analyst are likely to positively impact investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100